MPAM
EBS icon

Monarch Partners Asset Management’s Emergent Biosolutions EBS Stock Holding History

Monarch Partners Asset Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-98,785
Closed -$6.5M – 188
2018
Q3 		$6.5M Buy
98,785
+34,100
+53% +$1.99M 0.59% 71
2018
Q2 		$3.27M Sell
64,685
-870
-1% -$45.3K 0.3% 103
2018
Q1 		$3.45M Buy
+65,555
New +$3.27M 0.32% 106

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Monarch Partners Asset Management's EBS Position: Q4 2018 in Review

Monarch Partners Asset Management sold out of Emergent Biosolutions (EBS) in Q4 2018, closing a stake of 98,785 shares — an estimated $6.5M sold.

Monarch Partners Asset Management first reported a position in EBS in Q1 2018 and held it in 3 quarters. The position peaked at $6.5M in Q3 2018. 297 funds tracked by Wall St. Rank hold EBS as of Q4 2018.

  • Monarch Partners Asset Management reported no remaining Emergent Biosolutions position as of Q4 2018 after selling out during the quarter.
  • Monarch Partners Asset Management sold 98,785 Emergent Biosolutions shares in Q4 2018, an estimated $6.5M.
  • Monarch Partners Asset Management first reported a position in Emergent Biosolutions in Q1 2018 and held it in 3 quarters.
  • Monarch Partners Asset Management's Emergent Biosolutions position peaked at $6.5M in Q3 2018.
  • 297 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2018.

Based on Monarch Partners Asset Management's 13F filing for Q4 2018, filed 7 Feb 2019.